Thales Unveils New Secrets Management Solution to Help Reduce Risks and Improve DevOps and Cloud Security
24.4.2023 16:00:00 EEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced the introduction of a new secrets management solution as part of its CipherTrust Data Security platform which unifies the discovery, classification, protection, and control of sensitive data across cloud, on-premises and hybrid environments. Thales’s new secrets management solution, powered by Akeyless’ Vault Platform, enables customers to manage and secure DevOps and cloud workloads’ secrets. The new capability enhances the capabilities of the CipherTrust Data Security platform to help security and governance teams reduce risks by streamlining security processes across their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230424005088/en/
@Thales
Thales’ new secrets management solution helps ensure that only authorized workloads and applications can access their passwords, API keys, and certificates, protecting them from unauthorized access, theft, or misuse. The process of secrets management typically involves generating and storing secrets securely, controlling access, and monitoring to alert when there is a suspicion of a breach and associated details.
Todd Moore, vice president of data security products at Thales: "Combining secrets management with key management is like having a fortified vault for all your valuable assets. We are pleased to meet our customers growing business needs by offering a single data security platform that can simplify the management of all their sensitive data, improve security and compliance, foster development collaboration, and scale their security infrastructure."
The addition of secrets management enables the CipherTrust Data Security Platform to solve several pain points for customers related to the storing and managing of secrets securely, including:
- Mitigating the risk of data breaches: By providing secure storage and access control to sensitive data such as passwords, API keys, and certificates, which are valuable targets for attackers, it mitigates the risk of data breaches.
- Simplifying the management of secrets: In many organizations, passwords and certificates are managed manually or with ad-hoc processes, which are time-consuming and error-prone, especially in large or complex environments.
- Ensuring compliance with regulations and standards: Some industries and regions require compliance with specific regulations and standards for data security which could be very complex to navigate.
- Enabling collaboration: Multiple teams or individuals who need access to secrets now have a centralized and secure way to collaborate on projects.
With support for secrets management, the CipherTrust Data Security Platform further simplifies customers' processes by allowing centralized management of secrets and keys and scaling up to encryption solutions and other data security use cases.
Shai Onn, President & Co-founder at Akeyless : “As enterprises increasingly adopt DevOps practices, Automation, containerization, and more cloud technologies, they face a new rising threat in the form of Secrets Sprawl, where credentials, certificates and keys of all forms are being found in large quantities within source code, configuration files, and DevOps automation platforms. In recent years, Akeyless has pioneered the SaaS based Secrets Management market, becoming the perfect choice for reputable enterprises globally, making it a natural partner for Thales. With Akeyless Vault Platform’s secrets management solution, Thales can offer a more holistic and cohesive platform for its customers enabling them to centralize and streamline their DevOps Security efforts, Cloud IAM initiatives and Encryption solutions projects.
For a demo, visit Thales’ booth #N-5369 and Akeyless.io’s booth #S-1861 at RSA 2023 (April 24 – 27 in San Francisco, USA) or learn more here.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005088/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
